PAX‐5 is invariably expressed in B‐cell lymphomas without plasma cell differentiation

Dong, Henry Y.; Browne, Patrick; Liu, Z; Gangi, Maryann D.

doi:10.1111/j.1365-2559.2008.03091.x

Cited by 30 publications

(36 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immunophenotypic expression patterns of DLBCL include positivity for various pan B-cell markers such as CD19, CD20, CD22, CD79a, PAX-5, and demonstration of immunoglobulin surface light chain restriction by flow cytometry in the majority of cases 63. The presence of positive PAX-5 immunostaining has been strongly associated with B-cell differentiation as PAX-5 is a B-cell restricted transcription factor 81,82. Staining for CD10, bcl-6, and MUM-1 are usually routinely performed in order to distinguish GCB from non-GCB DLBCL.…”

Section: Biomarkers Used In Hiv-nhl Diagnosis/prognosismentioning

confidence: 99%

Biomarkers of HIV-associated Cancer

et al. 2014

View full text Add to dashboard Cite

Cancer biomarkers have provided great opportunities for improving the management of cancer patients by enhancing the efficiency of early detection, diagnosis, and efficacy of treatment. Every cell type has a unique molecular signature, referred to as biomarkers, which are identifiable characteristics such as levels or activities of a myriad of genes, proteins, or other molecular features. Biomarkers can facilitate the molecular definition of cancer, provide information about the course of cancer, and predict response to chemotherapy. They offer the hope of early detection as well as tracking disease progression and recurrence. Current progress in the characterization of molecular genetics of HIV-associated cancers may form the basis for improved patient stratification and future targeted or individualized therapies. Biomarker use for cancer staging and personalization of therapy at the time of diagnosis could improve patient care. This review focuses on the relevance of biomarkers in the most common HIV-associated malignancies, namely, Kaposi sarcoma, non-Hodgkin’s lymphoma, and invasive cervical cancer.

show abstract

Section: Biomarkers Used In Hiv-nhl Diagnosis/prognosismentioning

confidence: 99%

Biomarkers of HIV-associated Cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

“…It has been reported that PAX5 is expressed in most B-LPDs (Dong et al, 2008). Moreover, a large proportion of B-LPDs show a limited response to chemotherapy.…”

Section: Pax5-positive Cells Are More Resistant To Chemotherapy Drugsmentioning

confidence: 99%

“…Deregulation of PAX5 has been associated with various types of tumorigenesis (Cazzaniga et al, 2001;Kanteti et al, 2009;Kozmik et al, 1995;Kubetzko et al, 2004;Stuart et al, 1995), especially in B-cell malignancies, such as lymphoma and lymphocytic leukemia (Cobaleda et al, 2007;Krenacs et al, 1998). PAX5 expression is prevalent in B-LPDs, but not in plasma B-cell malignancies (Dong et al, 2008). In addition, about 30% of multiple myeloma cases have been found to be accompanied by PAX5 expression (Lin et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

PAX5 interacts with RIP2 to promote NF-κB activation and drug-resistance in B-lymphoproliferative disorders

Wang

Chen

et al. 2016

Journal of Cell Science

View full text Add to dashboard Cite

Paired box protein 5 (PAX5) plays a lineage determination role in B-cell development. However, high expression of PAX5 has been also found in various malignant diseases, including B-lymphoproliferative disorders (B-LPDs), but its functions and mechanisms in these diseases are still unclear. Here, we show that PAX5 induces drug resistance through association and activation of receptor-interacting serine/threonine-protein kinase 2 (RIP2; also known as RIPK2), and subsequent activation of NF-κB signaling and anti-apoptosis gene expression in B-lymphoproliferative cells. Furthermore, PAX5 is able to interact with RIP1 and RIP3, modulating both RIP1-mediated TNFR and RIP2-mediated NOD1 and NOD2 pathways. Our findings describe a new function of PAX5 in regulating RIP1 and RIP2 activation, which is at least involved in chemotherapeutic drug resistance in B-LPDs.

show abstract

“…This marker is now routinely used in hematolymphoid cases and has been shown to be positive in cases of B-lymphoblastic leukemia, NHL of B-cell origin lacking plasmacytic differentiation, and cases of classical Hodgkin's lymphoma [11, 17, 18]. Importantly, this marker remains positive in cases of lymphoma in which patients have been treated with rituximab, a drug which targets the CD20 molecule.…”

Section: Discussionmentioning

confidence: 99%

PAX8 Distinguishes Diffuse Large B-Cell Lymphoma Mimicking Sarcoma

Hirsch

Nascimento²

2017

Case Reports in Pathology

View full text Add to dashboard Cite

PAX8 is important for embryogenesis of the thyroid, Müllerian system, and upper urinary/renal tract, and expression of PAX8 has been described in carcinomas from each of these sites. The sensitivity and specificity of the polyclonal PAX8 antibody in a large cohort of epithelial tumors as well as lymphomas have been previously determined, the latter because polyclonal PAX8 is known to be immunoreactive in nonneoplastic B-cell lymphocytes which are often used as the positive internal control for immunohistochemistry. In this case report, PAX8 was a diagnostic clue for revising a previous diagnosis of unclassified high grade sarcoma to diffuse large B-cell lymphoma. This case report demonstrates a pitfall for PAX8 immunoreactivity and acts as a reminder that lymphoma should be included in the differential diagnosis of a PAX8 positive, epithelial cell marker negative tumor of unknown primary origin.

show abstract

PAX‐5 is invariably expressed in B‐cell lymphomas without plasma cell differentiation

Abstract: PAX-5 is the most sensitive and reliable immunohistochemical marker for B-cell malignancies. Lack of PAX-5 expression correlates with the presence of marked plasma cell differentiation.

Cited by 30 publications

References 48 publications

Biomarkers of HIV-associated Cancer

Biomarkers of HIV-associated Cancer

PAX5 interacts with RIP2 to promote NF-κB activation and drug-resistance in B-lymphoproliferative disorders

PAX8 Distinguishes Diffuse Large B-Cell Lymphoma Mimicking Sarcoma

Contact Info

Product

Resources

About